Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection shows promise for controlling high blood pressure

NCT ID NCT04936035

Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called ALN-AGT01 in 394 adults with mild-to-moderate high blood pressure. The goal was to see if it could safely lower blood pressure over three months. Participants received either the drug or a placebo, and blood pressure was measured continuously over 24 hours. The study has been completed, and results will help determine if this approach can help manage hypertension long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

394 people

The number who actually took part.

Started

Jul 2021

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive medication Exclusion Criteria: * Secondary hypertension, orthostatic hypotension * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2× upper limit of normal (ULN) * Elevated potassium \>5 mEq/L * Estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73m\^2 * Received an investigational agent within the last 30 days * Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus * History of any cardiovascular event within 6 months prior to randomization * History of intolerance to SC injection(s)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

Contacts and locations

Locations

  • Clinical Trial Site

    Birmingham, Alabama, 35209, United States

  • Clinical Trial Site

    Tempe, Arizona, 85281, United States

  • Clinical Trial Site

    Tempe, Arizona, 85282, United States

  • Clinical Trial Site

    Beverly Hills, California, 90211, United States

  • Clinical Trial Site

    La Mesa, California, 91942, United States

  • Clinical Trial Site

    Los Angeles, California, 90057, United States

  • Clinical Trial Site

    San Diego, California, 92103, United States

  • Clinical Trial Site

    South Gate, California, 90280, United States

  • Clinical Trial Site

    Vista, California, 92083, United States

  • Clinical Trial Site

    Washington D.C., District of Columbia, 20011, United States

  • Clinical Trial Site

    Clearwater, Florida, 33756, United States

  • Clinical Trial Site

    Coral Gables, Florida, 33134, United States

  • Clinical Trial Site

    Fleming Island, Florida, 32003, United States

  • Clinical Trial Site

    Hollywood, Florida, 33021, United States

  • Clinical Trial Site

    Hollywood, Florida, 33024, United States

  • Clinical Trial Site

    Inverness, Florida, 34452, United States

  • Clinical Trial Site

    Jacksonville, Florida, 32204, United States

  • Clinical Trial Site

    Jacksonville, Florida, 32216, United States

  • Clinical Trial Site

    Jacksonville, Florida, 32256, United States

  • Clinical Trial Site

    Miami, Florida, 33126, United States

  • Clinical Trial Site

    Miami, Florida, 33135, United States

  • Clinical Trial Site

    Naples, Florida, 34102, United States

  • Clinical Trial Site

    Orlando, Florida, 32801, United States

  • Clinical Trial Site

    Acworth, Georgia, 30101, United States

  • Clinical Trial Site

    Columbus, Georgia, 31904, United States

  • Clinical Trial Site

    Fayetteville, Georgia, 30214, United States

  • Clinical Trial Site

    Macon, Georgia, 31210, United States

  • Clinical Trial Site

    Champaign, Illinois, 61822, United States

  • Clinical Trial Site

    Valparaiso, Indiana, 46383, United States

  • Clinical Trial Site

    West Des Moines, Iowa, 50266, United States

  • Clinical Trial Site

    Lake Charles, Louisiana, 70601, United States

  • Clinical Trial Site

    New Orleans, Louisiana, 70124, United States

  • Clinical Trial Site

    Prairieville, Louisiana, 70769, United States

  • Clinical Trial Site

    Baltimore, Maryland, 21229, United States

  • Clinical Trial Site

    Jackson, Mississippi, 39209, United States

  • Clinical Trial Site

    Jefferson City, Missouri, 65109, United States

  • Clinical Trial Site

    Las Vegas, Nevada, 89119, United States

  • Clinical Trial Site

    New York, New York, 10036, United States

  • Clinical Trial Site

    The Bronx, New York, 10456, United States

  • Clinical Trial Site

    Greensboro, North Carolina, 27408, United States

  • Clinical Trial Site

    Greensboro, North Carolina, 27410, United States

  • Clinical Trial Site

    Medford, Oregon, 97504, United States

  • Clinical Trial Site

    Greenville, South Carolina, 29607, United States

  • Clinical Trial Site

    Memphis, Tennessee, 38119, United States

  • Clinical Trial Site

    Cedar Park, Texas, 78613, United States

  • Clinical Trial Site

    Houston, Texas, 77074, United States

  • Clinical Trial Site

    Houston, Texas, 77081, United States

  • Clinical Trial Site

    Magnolia, Texas, 77355, United States

  • Clinical Trial Site

    Pearland, Texas, 77584, United States

  • Clinical Trial Site

    San Antonio, Texas, 78229, United States

  • Clinical Trial Site

    Stephenville, Texas, 76401, United States

  • Clinical Trial Site

    Tomball, Texas, 77375, United States

  • Clinical Trial Site

    Waco, Texas, 76708, United States

  • Clinical Trial Site

    Burke, Virginia, 22015, United States

  • Clinical Trial Site

    Red Deer, Alberta, Canada

  • Clinical Trial Site

    New Minas, Nova Scotia, Canada

  • Clinical Trial Site

    Brampton, Ontario, Canada

  • Clinical Trial Site

    Toronto, Ontario, Canada

  • Clinical Trial Site

    Chicoutimi, Quebec, Canada

  • Clinical Trial Site

    Mirabel, Quebec, Canada

  • Clinical Trial Site

    Montreal, Quebec, Canada

  • Clinical Trial Site

    Québec, Quebec, Canada

  • Clinical Trial Site

    Trois-Rivières, Quebec, Canada

  • Clinical Trial Site

    Victoriaville, Quebec, Canada

  • Clinical Trial Site

    Bayamón, 00961, Puerto Rico

  • Clinical Trial Site

    Ponce, 00716, Puerto Rico

  • Clinical Trial Site

    San Juan, Puerto Rico

  • Clinical Trial Site

    Ivano-Frankivsk, Ukraine

  • Clinical Trial Site

    Kharkiv, Ukraine

  • Clinical Trial Site

    Odesa, Ukraine

  • Clinical Trial Site

    Uzhhorod, Ukraine

  • Clinical Trial Site

    Glasgow, United Kingdom

  • Clinical Trial Site

    Hexham, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

  • Clinical Trial Site

    Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.